<DOC>
	<DOCNO>NCT01497262</DOCNO>
	<brief_summary>This 4 month , open-label study evaluate safety tolerability fingolimod 0.5 mg patient relapsing-remitting multiple sclerosis ( RRMS ) generate additional data Multiple Sclerosis ( MS ) patient population closely resemble clinical population see routine medical care .</brief_summary>
	<brief_title>Safety Tolerability Fingolimod Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients relapse remit Multiple Sclerosis Patients Expanded Disability Status Scale ( EDSS ) score 06.5 . Patients MS relapse remit MS Patients history chronic disease immune system MS , require systemic immunosuppressive treatment , know immunodeficiency syndrome . Patients treat : systemic corticosteroid immunoglobulin within 1 month prior baseline ; immunosuppressive medication within 3 month prior baseline ; monoclonal antibody within 3 month prior baseline ; cladribine , mitoxantrone alemtuzumab time . Uncontrolled diabetes mellitus screen Diagnosis macular edema Screening Phase Patients active systemic bacterial , viral fungal infection , know AIDS , Hepatitis B , Hepatitis C infection positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test . Patients receive total lymphoid irradiation bone marrow transplantation . Patients certain cardiovascular condition and/or finding screen ECG Patients certain liver condition Pregnant confirm positive pregnancy test nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
</DOC>